Drugs agency clears flu jab in Italy scare

AFP - [email protected]
Drugs agency clears flu jab in Italy scare
The Novartis flu vaccine, Fluad, has been given the all clear by the European Medicines Agency. Photo: Sebastien Bozon/AFP

Europe's drugs watchdog on Wednesday said it found no evidence to link the Novartis flu vaccine Fluad to a scare in Italy, where 19 people are reported to have died after being given the jab.


The European Medicines Agency (EMA) said its Pharmacovigilance Risk Assessment Committee (PRAC) concluded "there is no evidence that Fluad... has caused serious events including deaths" in Italy.

EMA said that four million doses of Fluad had been distributed for the current vaccination campaign in Italy, and the vaccine had also been used in Austria, Germany and Spain.

"Fluad is used in older people (65 years of age and older), especially in those who have a number of illnesses at the same time and are at an increased risk of health complications," the statement noted.

"After the review of the cases reported, the PRAC concluded that there was no evidence for a causal relation between the reported fatal events and the administration of Fluad."

On Monday, the Italian Pharmaceutical Agency (AIFA) said it had been notified of 19 deaths among people who had died following vaccination with Fluad.

But it said preliminary tests ruled out any contamination in two batches of the drug that were taken out of circulation the previous week.

Novartis says there is no evidence to link the deaths to the vaccine, which has been in use since 1997 and of which 65 million doses have been given to people around the world.

EMA, citing World Health Organization (WHO) figures, said flu caused about three to five million cases of severe illness worldwide each year, resulting in between 250,000 and 500,000 deaths.

"Influenza vaccines are the most effective way to prevent the disease and the serious complications it can cause," the London-based agency said.



Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

See Also